REVIEW PAPER
Kawasaki disease – characteristics, diagnosis, and management
 
More details
Hide details
1
Praski State Hospital, Warsaw, Poland
 
2
Military Institute of Medicine-National Research Institute, Warsaw, Poland
 
3
University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland
 
4
St. John Paul II’s Western Hospital of Grodzisk Mazowiecki, Poland
 
5
The Rafal Mashtak Hospital of Grochów, Warsaw, Poland
 
6
The University Clinical Centre in Gdańsk, Gdańsk, Poland
 
 
Submission date: 2023-04-17
 
 
Final revision date: 2023-07-14
 
 
Acceptance date: 2023-07-17
 
 
Publication date: 2024-03-06
 
 
Corresponding author
Yevheniia Popravko
Yevheniia Popravko, Praski State Hospital, 67 Aleja Solidarności, 03-401 Warsaw, Poland
 
 
Pediatr Pol 2024;99(1):46-52
 
KEYWORDS
TOPICS
ABSTRACT
Kawasaki disease (KD) is an acute systemic vasculitis of medium – sized vessels that affects infants and children. The etiology of KD is unclear. Typical KD requires the presence of fever of at least 5 days duration and coexisting ≥ 4/5 principal clinical features: bilateral bulbar conjunctival injection, erythema and cracking og lips, skin rash, erythema and edema of the palms and feet, unilateral cervical nonpurulent lymphadenopathy. If patient presents less than 4 of the principal clinical features, the diagnosis of incomplete KD should be considered. The basis of initiate treatment of KD is a single dose of intravenous immunoglobulin (IVIG) with acetylsalicylic acid. But about 10–20% of patients do not respond to IVIG-therapy. Timely and adequate treatment of KD by IVIG and aspirin could help to prevent the development of coronary artery lesions, thats why diagnosis of KD is very important.
REFERENCES (21)
1.
Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr 2018; 6: 198.
 
2.
Rife E, Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep 2020; 22: 75.
 
3.
Burns JC. History of the worldwide emergence of Kawasaki disease. Int J Rheum Dis 2017; 21: 13-15.
 
4.
McCrindle BW. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation 2017; 135: e927-e999.
 
5.
Zhu F, Ang JY. 2021 update on the clinical management and diagnosis of Kawasaki disease. Curr Infect Dis Rep 2021; 23: 1-11.
 
6.
Burns JC, Hsieh LE, Kumar J, et al. Characterization of circulating immune cells in acute Kawasaki disease suggests exposure to different antigens. Clin Exp Immunol 2020; 202: 263-272.
 
7.
Owens AM, Plewa MC. Kawasaki Disease. NCBI Bookshelf. Available from: https://www.ncbi.nlm.nih.gov/b....
 
8.
Mamoru A, Ryuji F, Kenji H, et al. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Circulation J 2014; 78: 2521-2562.
 
9.
Lee W, Cheah CS, Suhaini SA, et al. Clinical manifestations and laboratory findings of Kawasaki disease: beyond the classic diagnostic features. Medicina 2022; 58: 734.
 
10.
Sosa TK. Kawasaki Disease Workup: approach considerations, diagnosis of incomplete Kawasaki disease, echocardiography. Medscape. Available from: https://emedicine.medscape.com....
 
11.
Wessels PA, Bingler MA. A comparison of Kawasaki disease and multisystem inflammatory syndrome in children. Progr Pediatr Cardiol 2022; 65: 101516.
 
12.
Kuo HC, Ksu YW, Wu MS, Chien SC, Liu FS, Chang WC. Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease. J Microbiol Immunol Infect 2016; 49: 1-7.
 
13.
Patel RM, Shulman ST. Kawasaki disease: a comprehensive review of treatment options. J Clin Pharm Ther 2015; 40: 620-625.
 
14.
Fukui S, Seki M, Minami T, et al. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial. Pediatr Rheumatol Online J 2021; 19: 107.
 
15.
Burns JC, Song Y, Bujold M, et al. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013; 174: 337-344.
 
16.
Han CL, Zhao SL. Intravenous immunoglobulin gamma (IVIG) versus IVIG plus infliximab in young children with Kawasaki disease. Med Sci Monit 2018; 24: 7264-7270.
 
17.
Mori M, Hara T, Kikuchi M, et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 2018; 8: 1994.
 
18.
Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health 2021; 5: 852-861.
 
19.
Portman MA, Dahdah NS, Slee A, et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics 2019; 143: e20183675.
 
20.
Zeng YY, Zhang M, Ko S, Chen F. An update on cardiovascular risk factors after Kawasaki disease. Front Cardiovasc Med 2021; 8: 671198.
 
21.
Gałeczka M, Fiszer R, Karwot B, Głowacki J, Szkutnik M. Difficult diagnosis of Kawasaki disease in a patient with giant coronary artery aneurysms. Kardiol Pol 2017; 75: 932-932.
 
Journals System - logo
Scroll to top